Tüdőrák: vizsgálatok itt: Spanyolország
275 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleDose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
- Where
- A Coruña, Barcelona, Girona, Málaga
- Életkor
- 18 év and over
- People
- 41 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to joinNCT05751798 · EU 2024-514826-22-00 - 2. fázisNot yet taking people in SpanyolországPhase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
- Where
- Madrid, Palma
- Életkor
- 18 év and over
- People
- 158 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT07234877 · EU 2025-522985-60-00 - 1. fázisNot yet taking people in SpanyolországAn Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib, Osimertinib or Docetaxel in Patients with Advanced NSCLC
- Where
- Barcelona, Madrid, Pozuelo de Alarcón
- Életkor
- 18 év and over
- People
- 40
- Run by
- TOLREMO therapeutics AG
See details and how to join2024-519071-25-00 - 1/2. fázisNot yet taking people in SpanyolországA clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer
- Where
- Barcelona, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 25 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-523276-23-00 - 2. fázisTaking peopleNiraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
- Where
- A Coruña, Jaén, Majadahonda
- Életkor
- 18 év and over
- People
- 44 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT05718323 · EU 2022-502092-33-00 - 1/2. fázisNot yet taking people in SpanyolországA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Badalona, Hortaleza
- Életkor
- 18 év and over
- People
- 252 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07223047 - 1/2. fázisFut, nem toborozA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Barcelona, Madrid
- Életkor
- 12 év and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - 3. fázisNot yet taking people in SpanyolországPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Nuvation Bio Inc.
See details and how to joinNCT07154706 · EU 2025-521971-29-00 - 3. fázisTaking peopleStudy of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
- Where
- A Coruña, Alicante, Badalona, Barcelona, Bilbao, Elche, Granada, Jerez de la Frontera, Las Palmas De Gran Canaria, León, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Ourense, Palma, Reus, Sabadell, Salamanca, Santa Cruz de Tenerife, Sevilla, Terrassa, Valencia, Valladolid, Vigo, Zaragoza
- Életkor
- 18 év and over
- People
- 129
- Run by
- Fundación GECP
See details and how to joinNCT06431633 · EU 2024-512960-75-00 - 1. fázisTaking peoplePhase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 76 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2023-510356-23-00 - 3. fázisTaking peopleEfficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Oviedo, Santiago de Compostela, Seville, Valencia
- Életkor
- 18 év and over
- People
- 170 worldwide
- Run by
- Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT05918302 · EU 2022-502154-13-00 - 2. fázisFut, nem toborozPhase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
- Where
- A Coruña, Barcelona, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Advenchen Pharmaceuticals, LLC.
See details and how to joinNCT05363280 · EU 2023-509067-24-01 - No phaseTaking peopleConcomitant Use of Radiotherapy and Integrated Exercise - Lung Cancer
- Where
- Barcelona, Pamplona
- Életkor
- 18 év and over
- People
- 10
- Run by
- University of Deusto
See details and how to joinNCT07489391 - 2. fázisTaking peopleStudy for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
- Where
- Alicante, Badalona, Barcelona, Elche, Granada, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Málaga, Murcia, Santa Cruz de Tenerife, Santiago de Compostela, Valencia, Vigo
- Életkor
- 18 év and over
- People
- 68
- Run by
- Fundación GECP
See details and how to joinNCT07247786 · EU 2025-521251-24-00 - 1/2. fázisTaking peoplePhase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)
- Where
- Badalona, Barcelona, Las Palmas De Gran Canaria, Málaga, Murcia, Pamplona, Santa Cruz de Tenerife, Valencia
- Életkor
- 18 év and over
- People
- 60
- Run by
- Idp Discovery Pharma S.L.
See details and how to join2025-521902-17-00 - 2. fázisFut, nem toborozClinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
- Where
- A Coruña, Alicante, Badalona, Barcelona, Bilbao, Girona, Granada, Jaén, Leganés, Lugo, Madrid, Majadahonda, Palma, Sabadell, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 19
- Run by
- Fundación GECP
See details and how to joinNCT05398094 · EU 2024-511268-10-00 - 2. fázisFut, nem toborozSafety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
- Where
- L'Hospitalet de Llobregat, Madrid, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06841055 · EU 2024-518279-80-00 - 2/3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Adult Participants with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2024-518586-10-00 - 1. fázisVisszavonvaPhase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
- Where
- Badalona, Madrid, Seville, Valencia
- Életkor
- 18 év and over
- People
- 304 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT04686305 · EU 2023-504949-31-00 - 3. fázisTaking peopleDose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial
- Where
- Almería, Barakaldo, Girona, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca, Santander, Santiago de Compostela, Seville, Valencia
- Életkor
- 18 év and over
- People
- 300
- Run by
- Instituto de Investigación Biomédica de Salamanca
See details and how to joinNCT07015892 - No phaseNot yet taking people in SpanyolországEffectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficacy of Chemotherapy in Adults With Breast, Lung and Colon Cancer
- Where
- Vic
- Életkor
- 35 év to 65 év
- People
- 70
- Run by
- University of Vic - Central University of Catalonia
See details and how to joinNCT07502963 - No phaseTaking peopleUnveiling Malnutrition and Metabolic Changes in Lung Cancer Patients: Setting the Basis for Precision Nutrition Models.
- Where
- Madrid, San Sebastián de los Reyes
- Életkor
- 18 év to 85 év
- People
- 180 worldwide
- Run by
- Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares
See details and how to joinNCT07486947 - No phaseTaking peopleClinical Outcomes and Quality Of Life After Minimally Invasive Segmentectomy Versus Lobectomy for Lung Cancer
- Where
- Madrid
- Életkor
- 18 év and over
- People
- 180
- Run by
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
See details and how to joinNCT07477158 - No phaseTaking peopleProspective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
- Where
- Barcelona, Elche, Madrid, Oviedo, Santander, Toledo, Valencia
- Életkor
- 45 év and over
- People
- 1200
- Run by
- Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)
See details and how to joinNCT07465848 - No phaseTaking peoplePathological Response After Neoadjuvant Treatment on NSCLC
- Where
- A Coruña, Alicante, Badalona, Barakaldo, Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Valencia, Vigo
- Életkor
- 18 év and over
- People
- 150
- Run by
- Fundación GECP
See details and how to joinNCT05167487